SLS — Recent News Coverage
All news mentioning SLS in ESEN's AI-graded feed
News stories with SLS as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on SLS. See /coverage/SLS for the 30-day aggregate.
INVESTORIDEAS.COM
·
2026-11-17
HIGH
BULLISH
CORR0.42
SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial - Stock Soars with Triple Digit Gains
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) disclosed Phase 3 trial data for its GPS cancer vaccine in acute myeloid leukemia (AML), demonstrating a 41% reduction in mortality risk. This represents a pivotal efficacy readout—a potential…
RTTNEWS.COM
·
2026-11-17
HIGH
BULLISH
CORR0.42
SELLAS Gets A REGAL Boost As Immunotherapeutic Cancer Vaccine Trial Meets Primary Endpoint
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) announced Phase 3 REGAL trial success for Galinpepimut-S (GPS), its investigational cancer immunotherapy vaccine. Meeting the primary endpoint represents a pivotal regulatory milestone that ma…
SEEKINGALPHA.COM
·
2026-08-13
HIGH
BULLISH
CORR0.42
This One Data Readout Will Make Or Break Sellas Life Sciences Group (NASDAQ:SLS)
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) faces a critical inflection point with the Phase 3 REGAL trial readout for GPS (its acute myeloid leukemia therapeutic candidate). This represents a binary catalyst event where efficacy/safety…
SEEKINGALPHA.COM
·
2026-08-02
NEUTRAL
BULLISH
CORR0.35
SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) is navigating a critical inflection point ahead of its REGAL clinical readout, a defining catalyst for the biotech firm's pipeline validation and shareholder returns. The company's institution…
INSIDERMONKEY.COM
·
2026-07-17
NEUTRAL
BULLISH
CORR0.35
Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result
$SLS
◈ ESEN AI
Sellas Life Sciences (SLS) experienced a sharp single-day rally of 12.26%, closing at $13.19, driven by pre-event positioning ahead of a material clinical trial announcement. The stock's movement reflects typical pre-ca…
SEEKINGALPHA.COM
·
2026-07-14
NEUTRAL
BULLISH
CORR0.35
SELLAS: Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) is positioned at an inflection point driven by Phase 3 trial data for its GPS candidate in acute myeloid leukemia (AML) CR2 patients. The REGAL trial represents a binary event catalyst with po…
RTTNEWS.COM
·
2026-06-30
NEUTRAL
BULLISH
CORR0.45
Top Biotech Gainers: UPC Expands Patent Portfolio, All Eyes On SLS, What's Behind The QDEL Rumor?
$UPC
$SLS
$QDEL
◈ ESEN AI
Universe Pharma (UPC) has expanded its patent portfolio, a strategic move that strengthens its intellectual property moat and potentially extends market exclusivity for pipeline assets. Patent expansion typically signal…
INSIDERMONKEY.COM
·
2026-06-29
LOW
NEUTRAL
CORR0.35
Is SELLAS Life Sciences Group, Inc. (SLS) A Good Stock To Buy Now?
$SLS
◈ ESEN AI
This article presents a curated bullish thesis on SELLAS Life Sciences (SLS), a small-cap biopharmaceutical company, based on analysis from independent research platform BioEquity Watch. The piece functions primarily as…
SEEKINGALPHA.COM
·
2026-06-27
NEUTRAL
BULLISH
CORR0.42
SELLAS Life Sciences: The AML Platform Is More Interesting Than Binary Event (NASDAQ:SLS)
$SLS
◈ ESEN AI
SELLAS Life Sciences (SLS) is positioning its acute myeloid leukemia (AML) platform as a multi-asset opportunity rather than a single binary catalyst event. The company's dual-path franchise structure reduces idiosyncra…
RTTNEWS.COM
·
2026-06-26
NEUTRAL
BULLISH
CORR0.35
Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS?
$TECH
$SLS
$KYMR
$MSLE
◈ ESEN AI
TECH (Bio-Techne) leads biotech gainers following acquisition announcement, representing a material capital event for the company and signaling continued consolidation appetite within the life sciences research tools se…
INSIDERMONKEY.COM
·
2026-06-26
NEUTRAL
BULLISH
CORR0.32
9 Stocks Winning by Double Digits
$AMAT
$MU
$TER
$SLS
◈ ESEN AI
Nine equities delivered double-digit appreciation on Thursday despite broader market underperformance, signaling selective strength within technology and industrial subsectors. The gains were anchored in earnings beats …
INSIDERMONKEY.COM
·
2026-06-22
LOW
NEUTRAL
CORR0.35
10 Stocks That Will 10X According to Social Media
$SLS
◈ ESEN AI
This article addresses retail investor behavior and social media-driven stock selection, a phenomenon that has matured from pandemic-era novelty into a recognized market microstructure dynamic. The piece acknowledges th…
EXPLORE OTHER FILTERS